ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0006281;DNA repair;7.0;0.6281612110245125;0.6649999707694567;8.781226392104918;180.342582143442;3.582668236575797;0.006035903926554339;0.534137185486798;[UPF1, AQR, WDR48, DCLRE1C, UBE2B, NCOA6, INTS3, CIB1, YY1, SETX, CDK9, POLB, DDB1, NIPBL, HIST3H2A, COPS5, POLR2B, EP300, POLR2G, USP51]
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[ERN1, EXTL2, CTDSP2, SYVN1]
GO:0030031;cell projection assembly;4.0;0.6729672293956388;0.5864836146978194;8.124446855715847;35.515967283127445;3.9749552523034066;0.0011886874626708887;0.45327939645711923;[BBS2, ONECUT2, PARVG, TMEM107, IFT122, CCDC65, EMP3, FXYD5, SNAP29, DYNLL2]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[MAP3K3, SP1, CIB1]
GO:0008589;regulation of smoothened signaling pathway;6.0;0.7671156992804218;0.7066781622303554;9.0689084645567;41.8512380110395;5.500407508664414;0.0014007232725606145;0.6044114083783503;[CREBBP, IFT122, RORA]
GO:0050796;regulation of insulin secretion;9.0;0.8259837884571596;0.8092325194088689;9.533214072687796;205.48125160941495;4.61801832846594;0.006877272570246766;0.6324062972578516;[ITPR2, ARNTL]
GO:0050672;negative regulation of lymphocyte proliferation;8.0;0.7436939687323844;0.7468469843661922;9.271849308553389;262.9542115637972;5.514393750639154;0.008800840817614076;0.6570063528532206;[ITCH, GAL, LST1]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[MAP3K3]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[UPF2, UPF1, CASC3, SMG5, DCP2, RPL19]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[CDKN1C, CIITA, HDAC3, ZNF350, HDAC1, NAB1, FOXG1, ARID4A, OTUD7B, IKZF2, ARNTL, YY1, NIPBL, RXRA, SAP130, TPR, DPF2, TRIM24, WWC3, EP300, LRRFIP1, SUDS3, ZNF564, ZNF189, TLE4, IRX1, DR1, CREBBP, UBE2I, NFYC, EID1, ILF3, HIST3H2A, CNOT1, NFIC, SP3, MTF2, ZNF658, LCOR, TAF7]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[RIC8A, RXRA, ALS2, ELL, UBE2B, CCM2, EIF4E2, ATP7A, SEC24C]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[CDKN1C, CIITA, ONECUT2, ELL, ARID4A, RORA, DDX41, HOXC13, AATF, IKZF2, YY1, NIPBL, NUP62, ZXDC, DPF2, TRIM24, EP300, ZNF564, IER2, TBP, NCOA6, ARNT, SENP2, MED6, ILF3, GAL, KARS, MTF2, TFEC, HDAC3, ZNF350, HDAC1, WBP2, RLF, ARNTL, RXRA, TP53INP2, TP53INP1, DVL3, SCAP, TBX1, ZNF462, DR1, CREBBP, NFYC, PBX3, GRHL1, USF2, FLI1, SETX, CDK9, CD4, TFCP2, COPS5, SP1, NFIC, SP3, TAF7, CAMK1]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TNPO2, KPNB1, ARNTL]
GO:0032201;telomere maintenance via semi-conservative replication;8.0;0.8933024483968273;0.8216512241984136;9.55953138100517;216.32599304453976;6.7325511899570465;0.0072402363064467505;0.719302980950052;[UPF1]
GO:0032204;regulation of telomere maintenance;7.0;0.6519675769143192;0.6769031537143602;8.969278623607858;103.7409614847858;5.395046993006588;0.003472116620091941;0.6268223193749;[UPF1, GNL3L, SMG5, DCP2]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[ALS2, VDAC3, MBP, SNCB, SPG11, KCNK3, PAFAH1B1]
GO:0042267;natural killer cell mediated cytotoxicity;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;47.356962503066434;6.7325511899570465;0.001584994916478408;0.6674232935401965;[PRDX1, LYST]
GO:0046621;negative regulation of organ growth;6.0;0.811012628672052;0.7286266269261705;9.360260265897443;146.9345464739773;6.599019797332524;0.0049177670379774545;0.6605944919115335;[WWC3]
GO:0071361;cellular response to ethanol;6.0;1.0;0.8231203125901445;9.628524252492122;330.81194821622347;7.138016298065211;0.011071978195372667;0.6881587980249038;[TP53INP1, ITPR2]
GO:0032438;melanosome organization;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;22.01435712052086;6.558197802812269;7.368007211887049E-4;0.6585068532133508;[LYST]
GO:0045540;regulation of cholesterol biosynthetic process;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;116.98845768213258;6.039404009397101;0.0039154983958446;0.705096027081865;[SP1, NFYC, SCAP, KPNB1]
GO:0071243;cellular response to arsenic-containing substance;4.0;0.8653626801206646;0.6826813400603323;9.377209824211215;38.7152913866576;7.138016298065211;0.0012957659612112835;0.6150384854347593;[ZFAND2A, MKNK2]
GO:0033522;histone H2A ubiquitination;11.0;0.8259837884571596;0.845420846558242;9.474373572664863;343.5530125033966;6.641579411751319;0.011498410150850943;0.7720796323116529;[DDB1, UBE2B]
GO:0034058;endosomal vesicle fusion;7.0;1.0;0.8509193652572005;9.628524252492122;65.8060249050737;7.474488534686424;0.0022024684319953925;0.7331650565203278;[VPS41, VPS8, VPS11]
GO:0043923;positive regulation by host of viral transcription;11.0;1.0;0.9324289523296623;9.628524252492122;272.30213926078306;6.943860283624253;0.009113707545043459;0.7875382901567328;[SP1, EP300, CHD1]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[POLB, UPF1, NCOA6, NFIC]
GO:1900034;regulation of cellular response to heat;6.0;0.8653626801206646;0.7558016526504768;9.271849308553389;29.43425144606613;5.970411137910149;9.851379067933503E-4;0.6284474158353811;[CREBBP, EP300]
GO:0008203;cholesterol metabolic process;6.0;0.7980440201809971;0.722142322680643;9.223059144383958;82.64786032185484;5.058574756385375;0.0027661495067272364;0.581816060879476;[HSD3B7, RXRA, SNX17, SCAP]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[ANKRD17, MAP3K3, CD4, UBE2I, NUP62, ECT2]
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;7.0;1.0;0.8509193652572005;9.628524252492122;76.30875120206336;6.375876246018314;0.0025539852293156346;0.6769819729871445;[MKNK2, CASP2]
GO:0000398;mRNA splicing, via spliceosome;11.0;0.8259837884571596;0.845420846558242;9.4949928598676;356.66873027722005;4.19357731889877;0.011937381421361158;0.6468886914394342;[SF3B5, AQR, SF3B2, GPKOW, BUD31, CPSF2, DDX42, DDX41, CASC3, USP39, SRRM1, EFTUD2, PABPN1, PCF11, U2AF2, POLR2B, SNRPG, SNRPB2, POLR2G, SLU7, SMNDC1, RBM5]
GO:0042832;defense response to protozoan;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;69.6526388451159;6.832634648514029;0.0023312111388408135;0.6725415662651573;[LYST]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[CREBBP, EP300]
GO:0000045;autophagosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;62.10424204613046;5.769740442447999;0.0020785730910948433;0.618185107137305;[BECN1, NSFL1C, GABARAPL1, TP53INP2, TP53INP1, UBQLN1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[SETX, MAP3K3, KARS, PABPN1, PTPRA, IL5RA, NCAM1, CCM2, MBP, CALM1, GFRA2]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[ITGB3, NEDD9, CCM2]
GO:0048384;retinoic acid receptor signaling pathway;6.0;0.7866048967936545;0.7164227609869718;8.935377071932177;25.568165535828406;7.004484905440688;8.557434906291208E-4;0.6813299963962409;[TBX1, RXRA]
GO:0048147;negative regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.87354995152188;6.409777797693995;0.0021377902344145586;0.6509166472493662;[TP53INP1]
GO:2000134;negative regulation of G1/S transition of mitotic cell cycle;9.0;0.7980440201809971;0.7952626352707877;9.394909401310617;355.88113835876356;5.244474134527214;0.011911021428637128;0.6644432763129993;[CNOT6, CNOT1, CTDSP2, CASP2, EP300, CNOT10, CNOT8]
GO:0032782;bile acid secretion;9.0;1.0;0.896240625180289;9.628524252492122;69.42950734212523;8.16763571524637;0.002323743128241031;0.8139338954918922;[STARD10]
GO:0033194;response to hydroperoxide;4.0;0.7980440201809971;0.6490220100904985;9.34084218004034;25.335607989987928;6.781341354126479;8.479599988580431E-4;0.5967981122146513;[SP1, TP53INP1]
GO:0070979;protein K11-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;6.375876246018314;0.00527474598481953;0.7584915600596062;[UBE2B, ANAPC5, ANAPC11]
GO:1904761;negative regulation of myofibroblast differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;114.21841186311113;9.083926447120524;0.0038227874551613377;0.7876727335416686;[TP53INP1]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[TRUB2, SF3B5, SF3B2, AHCYL1, DDX42, DDX41, CASC3, USP39, EFTUD2, ALKBH5, PABPN1, PCF11, U2AF2, POLR2B, ARL6IP4, SNRPB2, POLR2G, ZNF326, SMNDC1, RBM5, AQR, GPKOW, WTAP, BUD31, CPSF2, SSU72, THOC2, SRRM1, ERN1, PAN3, SON, FASTKD5, SNRPG, SLU7]
GO:0000294;nuclear-transcribed mRNA catabolic process, endonucleolytic cleavage-dependent decay;10.0;1.0;0.9152410118609203;9.628524252492122;717.2549128915896;9.083926447120524;0.0240058764469685;0.8797934328124444;[UPF1]
GO:0001933;negative regulation of protein phosphorylation;9.0;0.6056485694559711;0.6990649099082746;8.75603614327636;664.693789818838;3.7392027077583316;0.02224670295966317;0.5874636255457587;[CDKN1C, ITCH, HDAC3, UBE2B, SNX25, CTDSP2, NUP62, STK38, TAF7, CIB1, CALM1, PAFAH1B1]
GO:0030595;leukocyte chemotaxis;6.0;0.6873818243518346;0.6668112247660618;8.768322987269011;62.06300720445581;4.857092701852345;0.002077192998052941;0.5715122592407831;[HSD3B7, LYST, CCR2]
GO:2001235;positive regulation of apoptotic signaling pathway;8.0;0.6997970393407541;0.724898519670377;9.176539128749065;291.4603159253591;4.6590798152637145;0.009754914476767216;0.6132655584219551;[HRK, ATPIF1, TP53INP1, CASP2, G0S2, SERINC3, BBC3]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[ERN1, CDKN1C, TP53INP1, PPM1G]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[SF3B5, SF3B2, DDX42, DDX41, CASC3, USP39, EFTUD2, PABPN1, PCF11, U2AF2, POLR2B, ARL6IP4, SNRPB2, POLR2G, ZNF326, SMNDC1, RBM5, AQR, GPKOW, WTAP, BUD31, CPSF2, THOC2, SRRM1, ERN1, SON, SNRPG, SLU7]
GO:0061418;regulation of transcription from RNA polymerase II promoter in response to hypoxia;12.0;0.8933024483968273;0.8947715367885583;9.557065288509976;532.6985892857467;6.311337724880743;0.017828942385788714;0.770882417347765;[CREBBP, EP300, ARNT]
GO:0051292;nuclear pore complex assembly;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;123.37008173774021;7.474488534686424;0.004129085609897011;0.7053660038532718;[AHCTF1, NUP153]
GO:0043666;regulation of phosphoprotein phosphatase activity;9.0;0.7436939687323844;0.7680876095464813;9.328419660041783;158.30216566976694;5.058574756385375;0.005298231022267458;0.6549363734696205;[NSFL1C, NUAK1, PPP1R7, CALM1]
GO:0060687;regulation of branching involved in prostate gland morphogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;105.64673904754125;7.8311634786251565;0.003535901280028912;0.7236063770733796;[RXRA]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RABGAP1, DOCK8, ARHGAP25, RIC8A, BCR, ABR, ALS2, DVL3, PKP4, EVI5L, DOCK2, ECT2, TBC1D22A]
GO:0032922;circadian regulation of gene expression;6.0;1.0;0.8231203125901445;9.628524252492122;31.18462308171688;5.769740442447999;0.0010437212702063816;0.618185107137305;[PPP1CB, PPP1CC, HDAC1, RORA, ARNTL]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[RXRA, ATPIF1]
GO:0018076;N-terminal peptidyl-lysine acetylation;10.0;0.9326813400603323;0.8815816818910864;9.585964638073326;676.4251839632358;8.67846133901236;0.022639342164106888;0.8590579283277371;[CREBBP, EP300]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[IFNAR2, BECN1, ITCH, ILF3, POLR3C, DDX41, SERINC3, LYST, UNC13D, EXOC1]
GO:0016573;histone acetylation;11.0;0.6913464685778243;0.7781021866185744;9.117698628726131;658.0665084312584;5.152100814396198;0.0220248938157869;0.6959076275750737;[POLE4, DR1, CREBBP, EP300]
GO:0019048;modulation by virus of host morphology or physiology;6.0;0.5173302570349838;0.5817854411076364;7.2718719382278;41.653513925674126;6.193554689224359;0.0013941056253635594;0.6398589874268261;[CD4, RXRA, PABPN1, KPNB1]
GO:0032007;negative regulation of TOR signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;5.926926025970411;0.008015432820232688;0.6781032725983739;[ARNTL]
GO:0010591;regulation of lamellipodium assembly;8.0;0.8933024483968273;0.8216512241984136;9.461470167828956;72.62159929772238;6.343086423195323;0.0024305795732986186;0.6993857346658935;[ARPC2, ATP7A, SSH3]
GO:0032481;positive regulation of type I interferon production;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;65.23665507211369;5.618190544320798;0.002183412136085803;0.610434838299289;[CREBBP, POLR3C, EP300, DDX41, LRRFIP1]
GO:1901796;regulation of signal transduction by p53 class mediator;7.0;0.7192862368539868;0.710562483684194;9.117698628726131;45.070113835906206;4.948759890378168;0.001508456149618737;0.6039991761920099;[NUAK1, TBP, CSNK2A1, TP53INP1, TRIM24, EP300, TAF7, SENP2, RFFL]
GO:0000422;autophagy of mitochondrion;6.0;0.8653626801206646;0.7558016526504768;9.446202695698167;99.5332381578633;6.015873511986907;0.003331287907044985;0.6307723637598831;[BECN1, GABARAPL1]
GO:0006656;phosphatidylcholine biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.398000593880289;749.286726231254;6.343086423195323;0.025077952412686653;0.6993857346658935;[STARD10]
GO:0006406;mRNA export from nucleus;9.0;0.8933024483968273;0.8428918493787028;9.523163736834295;121.36021434248079;5.132682728539097;0.004061817156940898;0.658726258611935;[UPF2, UPF1, CPSF2, NUP153, THOC2, CASC3, SMG5, SRRM1, ALKBH5, PABPN1, U2AF2, TPR, NUP62, SLU7]
GO:0051058;negative regulation of small GTPase mediated signal transduction;8.0;0.811012628672052;0.780506314336026;9.370695143190021;239.487551390376;5.75172193694532;0.008015432820232688;0.6691433273378073;[NUP62, ARHGAP25]
GO:0015918;sterol transport;6.0;0.7369933605727446;0.6916169928765168;8.801845679307654;36.24031281319753;5.69953618377475;0.0012129306556936802;0.6145948580839232;[OSBPL2]
GO:2001016;positive regulation of skeletal muscle cell differentiation;9.0;0.8653626801206646;0.8289219652406215;9.541512875502493;376.2972035421309;7.9853141584524145;0.01259432875705866;0.8046099625986299;[TBX1, ARNTL]
GO:0071447;cellular response to hydroperoxide;5.0;0.8653626801206646;0.7229223519212526;9.485423408851448;143.11325921270426;7.697632086000634;0.004789871992277907;0.6838982747154925;[TP53INP1]
GO:0015914;phospholipid transport;7.0;0.7763722522362496;0.7391054913753253;9.040737587590003;67.00175910617337;5.618190544320798;0.0022424885796152832;0.638233890966345;[TMEM30A, PITPNB, STARD10, ABCA12]
GO:0050767;regulation of neurogenesis;6.0;0.47270034079162526;0.5594704829859571;7.335989495351577;60.464536800347794;3.1570004211501135;0.002023693632157412;0.4845694609432947;[SEMA6B, TMEM30A, FOXG1, CIB1, THOC2, TRAK1, SSH3, CYB5D2, ARNTL, RAB21, SETX, EIF4ENIF1, PPP1CC, OLFM1, NIPBL, SYNJ1, DVL3, CAMK1, ECT2, PAFAH1B1, ZNF365, CCR2]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[MKLN1, CFDP1, EPB41, WIPF2, LST1]
GO:0045747;positive regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;187.6437959822434;5.926926025970411;0.006280268983073171;0.6540226378555745;[CREBBP, EP300]
GO:1904837;beta-catenin-TCF complex assembly;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;6.409777797693995;0.0013529121422039536;0.618037346520142;[TLE4, CREBBP, HDAC1, EP300]
GO:1904828;positive regulation of hydrogen sulfide biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;472.60876326137793;9.777073627680469;0.015817789986085514;0.8509193652572005;[SP1]
GO:0050770;regulation of axonogenesis;9.0;0.6324783794010864;0.7124798148808322;8.859391164954255;152.1280667645758;4.606589632642318;0.005091589488238978;0.6318218332219429;[RAB21, SEMA6B, OLFM1, TRAK1, SSH3, PAFAH1B1]
GO:0032465;regulation of cytokinesis;6.0;0.5930994877375815;0.6196700564589352;8.140447197062288;31.798591743249187;5.358233019883872;0.0010642702487719462;0.5971405984103235;[BECN1, AHCTF1, SPAST, NUP62, PKP4, CALM1, ECT2]
GO:0034644;cellular response to UV;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;66.19362175939281;5.420364800990877;0.0022154409498949313;0.628117073252615;[YY1, DDB1, CREBBP, HIST3H2A, TP53INP1, EP300]
GO:0100057;regulation of phenotypic switching by transcription from RNA polymerase II promoter;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;601.4715605901642;9.777073627680469;0.02013071184369174;0.9324289523296623;[SP1]
GO:0051865;protein autoubiquitination;10.0;1.0;0.9152410118609203;9.628524252492122;155.4032479663248;5.769740442447999;0.005201206855589802;0.7103058064080809;[ITCH, UBE2B]
GO:0090403;oxidative stress-induced premature senescence;6.0;1.0;0.8231203125901445;9.628524252492122;55.82928668984125;8.390779266560578;0.0018685559824130236;0.7522251544931926;[ARNTL]
GO:1903077;negative regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;218.53196919702376;6.686031174322154;0.007314068343020746;0.7169239451870815;[PPFIA1]
GO:0070936;protein K48-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;5.8650506222523235;0.00527474598481953;0.7323679139043926;[ITCH, UBE2B, SYVN1, RFFL]
GO:2000074;regulation of type B pancreatic cell development;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;87.86935712531108;7.697632086000634;0.0029409083056968813;0.7167775754447168;[ARNTL]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[CAMLG, ITGB3, NEDD9, GFRA2, SETX, BCR, SGPL1, CD4, SLC9A6, ARPC2, PTPRA, POLR2B, ELMO1, POLR2G, ATP6V1F, FAM83A]
GO:0045994;positive regulation of translational initiation by iron;10.0;1.0;0.9152410118609203;9.628524252492122;1474.0558344206913;9.083926447120524;0.049335322213937396;0.8797934328124444;[RXRA]
GO:0007288;sperm axoneme assembly;8.0;1.0;0.875;9.628524252492122;92.78469724802203;7.379178354882098;0.0031054203160851054;0.7523715242355574;[BBS2, UBE2B, IQCG]
GO:0046604;positive regulation of mitotic centrosome separation;10.0;1.0;0.9152410118609203;9.628524252492122;603.270018576253;7.8311634786251565;0.020190904613979026;0.8157270763441555;[NSFL1C]
GO:0045637;regulation of myeloid cell differentiation;6.0;0.620063164412167;0.633151894796228;8.465373442686442;67.16582126229967;4.39257856489138;0.002247979592334476;0.5477569846744829;[CD4, CREBBP, HDAC1, EP300, ARNT, CIB1, C1QC]
GO:0006513;protein monoubiquitination;10.0;0.8653626801206646;0.8479223519212526;9.574457031221845;155.4032479663248;5.649939242635378;0.005201206855589802;0.704179167478338;[DDB1, UBE2B]
GO:0006995;cellular response to nitrogen starvation;7.0;0.8259837884571596;0.7639112594857803;9.405380701177911;176.14763520758262;7.212124270218933;0.005895502827818261;0.7197477358342742;[BECN1, GABARAPL1]
GO:0006511;ubiquitin-dependent protein catabolic process;8.0;0.7369933605727446;0.7434966802863723;9.190269321560967;156.4521708431119;3.582668236575797;0.005236313360306564;0.5582178202295975;[RNF38, ANAPC11, ARNTL, PSMD8, TRIM9, TP53INP2, PSMB1, UBQLN1, USP51, RFFL, C18orf25, USP46, UBE2I, LRRC29, UBE2B, SYVN1, FBXL15, DDB1, KBTBD4, NSFL1C, ITCH, KCTD10, FBXL3, ANAPC5, MAN1B1]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[BCR, UPF1, PABPN1]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[YY1, UPF1, RORA]
GO:0031124;mRNA 3'-end processing;9.0;0.8436909121759173;0.8180860812682478;9.52844079393514;355.1646528804444;5.407625775213448;0.011887041304472852;0.6727868588050205;[AHCYL1, PABPN1, PCF11, U2AF2, CPSF2, SSU72, THOC2, CASC3, SLU7, SRRM1]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[MAP3K3]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[RAB3B, TRAM1, AHCTF1, AHCYL1, SYS1, SFT2D3, CLTA, LYST, EIF4ENIF1, NUP62, TMED2, EVI5L, TNPO2, SNAP29, TBC1D22A, RAB8B, VPS18, TMED9, PDCD6IP, SSR2, VPS33B, COG3, RHBDF2, COG1, SENP2, BCR, GAL, ACOX2, SLU7, VAMP5, KPNB1, ACOT4, PAFAH1B1, EXOC1, RABGAP1, SUCNR1, HSD17B4, ZDHHC24, TRAK1, NAPG, ARNTL, RAB21, AP3M1, SNX25, VPS8, VPS11, ECT2, ATP6V1F, RPL19, PEX16, BBS2, PEX19, SYVN1, NUP153, ARCN1, PAN3, SNX17, VPS41, RAB18, SEC24C]
GO:0008064;regulation of actin polymerization or depolymerization;9.0;0.6729672293956388;0.7327242398781084;9.05316010758856;119.88573797499163;4.556717802602145;0.004012467759863614;0.6292713855144111;[MTPN, ARPC2, WIPF2, IQGAP2, SSH3]
GO:1901985;positive regulation of protein acetylation;9.0;0.7586651285174919;0.775573189439035;9.318369324188282;446.38867377971013;6.166155715036245;0.01494022718768261;0.711578115202808;[WBP2, CAMK1, ARNTL]
GO:0060528;secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development;7.0;1.0;0.8509193652572005;9.628524252492122;72.45322871866053;8.390779266560578;0.002424944361541102;0.7800242071602487;[RXRA]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[MAP3K3, CIB1]
GO:0032968;positive regulation of transcription elongation from RNA polymerase II promoter;12.0;1.0;0.9481203125901445;9.628524252492122;3433.0515732151193;6.8867018697843045;0.11490114660968445;0.8003065664753022;[CDK9, ELL]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[BECN1, CREBBP, ITPR2, ARNT, RORA, TM9SF4, NPEPPS, ALKBH5, NPPA, UBQLN1, EP300, SCAP, ATP7A, KCNK3]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[RAB3B, PRKCSH, MAST3, DOCK8, DGKA, IL5RA, DEFB1, BBC3, POLB, AKAP11, RPS6KA2, CASP2, EP300, RAB8B, CCR2, IFNAR2, GFRA2, ERN1, BCR, GAL, KARS, ALS2, ELMO1, DOCK2, KPNB1, EXOC1, CLEC16A, ITPR2, KRCC1, CRHR1, RAB21, ABR, NUAK1, GNG2, PABPN1, TIFA, STK38, MKNK2, DVL3, STK38L, NCAM1, MBP, ECT2, MAP3K3, IFT122, CNOT10, SETX, CNOT6, SNRK, ITCH, IRAK1BP1, PTPRA, CNOT1, RAB18, CCM2, NMUR1, CAMK1, CNOT8, CALM1]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[PARVG, ITGB3, LST1, THOC2, ECT2]
GO:0006699;bile acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;493.34951140512965;6.481236761676141;0.01651196416099542;0.7064507494004503;[HSD3B7, ACOX2, OSBPL2, HSD17B4]
GO:0045141;meiotic telomere clustering;7.0;0.9326813400603323;0.8172600352873667;9.57973408832269;114.35065953234648;7.57984905034425;0.00382721366563547;0.738553198190834;[UBE2B]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[PPFIA1, CLASP1]
GO:0006449;regulation of translational termination;8.0;0.8653626801206646;0.8076813400603323;9.4949928598676;233.78685173077864;7.697632086000634;0.00782463553292257;0.7686572628545723;[UPF1]
GO:0015711;organic anion transport;6.0;0.43219213062620165;0.5392163779032453;6.26616670414623;28.19857810171702;3.758480413184235;9.437810319917961E-4;0.5153291757075998;[SLC23A2, TMEM30A, RXRA, PITPNB, ABCC5, STARD10, SERINC3, ABCA12]
GO:0051017;actin filament bundle assembly;6.0;0.7866048967936545;0.7164227609869718;9.143016436710422;39.792633402144126;5.734022359845919;0.001331823628924752;0.6163584827319739;[NEDD9]
GO:0033128;negative regulation of histone phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.60383163990175;1476.02840938532;8.67846133901236;0.0494013425228013;0.8590579283277371;[UBE2B]
GO:0033364;mast cell secretory granule organization;6.0;1.0;0.8231203125901445;9.628524252492122;22.861654980906852;9.083926447120524;7.651590180572567E-4;0.7876727335416686;[LYST]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[CDKN1C, BECN1, ATPIF1, LST1, IFT122, CIB1, EMP3, COMT, ITCH, GAL, KARS, ADORA3, RPS6KA2, FNTB, NUP62, TP53INP1, TRIM24, CNOT8, RBM5]
GO:1905564;positive regulation of vascular endothelial cell proliferation;8.0;1.0;0.875;9.628524252492122;108.29290547333461;7.138016298065211;0.0036244660889050463;0.7400384854347593;[SP1]
GO:0042795;snRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1410.6487555617684;5.528578385631111;0.047213144347195396;0.730852068336507;[CDK9, TBP, ELL, POLR2B, SP1, INTS3, INTS10, INTS4, POLR2G]
GO:1901522;positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus;12.0;0.7140352122741334;0.8051379187272112;9.260799472366804;1467.8987330058965;6.641579411751319;0.04912924957061573;0.7877709925721352;[RXRA, EP300]
GO:0042796;snRNA transcription by RNA polymerase III;12.0;1.0;0.9481203125901445;9.628524252492122;1408.2738498071953;7.9853141584524145;0.047133658388866254;0.8564896500084854;[ELL]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[CIITA, HDAC3, ZNF350, ONECUT2, ELL, HDAC1, WBP2, ARID4A, RORA, DDX41, HOXC13, AATF, IKZF2, RLF, ARNTL, YY1, NIPBL, RXRA, DPF2, EP300, SCAP, ZNF564, IER2, TBX1, ZNF462, DR1, CREBBP, NCOA6, NFYC, PBX3, ARNT, SENP2, GRHL1, USF2, FLI1, MED6, SETX, CDK9, TFCP2, GAL, COPS5, SP1, NFIC, SP3, MTF2, TFEC, TAF7, CAMK1]
GO:0045945;positive regulation of transcription by RNA polymerase III;11.0;1.0;0.9324289523296623;9.628524252492122;1460.8767565828284;7.379178354882098;0.04889423033910414;0.8098004765652196;[ELL]
GO:0043401;steroid hormone mediated signaling pathway;6.0;0.7508913569872202;0.6985659910837546;8.801845679307654;25.735219620490994;4.909539177224887;8.613346405038622E-4;0.5741943744303455;[RXRA, NCOA6, WBP2, TAF7, RORA]
GO:0006301;postreplication repair;8.0;0.8259837884571596;0.7879918942285797;9.500690880982237;183.0506323445446;5.8067817141283475;0.006126539929698291;0.6719590869034888;[UBE2B]
GO:0001893;maternal placenta development;4.0;1.0;0.75;9.628524252492122;43.252245699280884;7.379178354882098;0.001447613739060994;0.6273715242355574;[RXRA, TMED2]
GO:0006417;regulation of translation;7.0;0.5221699919663294;0.6120043612403652;8.01908634005802;212.8215771898108;3.9901762463137618;0.007122946661558481;0.554977164055858;[MTPN, UPF1, CNOT10, CASC3, EIF4ENIF1, ATXN2, CNOT6, ILF3, RXRA, CNOT1, TPR, MKNK2, POLR2G, EIF4E2, CNOT8]
GO:0051026;chiasma assembly;4.0;1.0;0.75;9.628524252492122;42.501794097528276;7.697632086000634;0.0014224967993129276;0.6436572628545723;[UBE2B]
GO:2000778;positive regulation of interleukin-6 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;618.0674169630446;6.599019797332524;0.02068616022119099;0.7527151911823093;[MBP]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[TP53INP2, HSD17B4, SND1]
GO:0034446;substrate adhesion-dependent cell spreading;6.0;1.0;0.8231203125901445;9.628524252492122;56.23121614310476;6.088194173566533;0.0018820081995007299;0.63447084575632;[PARVG, ITGB3]
GO:0051028;mRNA transport;8.0;0.8653626801206646;0.8076813400603323;9.446202695698167;42.48893056556077;4.77312732173501;0.0014220662684744023;0.6190979532066485;[UPF2, UPF1, AHCTF1, CPSF2, NUP153, THOC2, CASC3, SENP2, SMG5, SRRM1, ALKBH5, PABPN1, U2AF2, TPR, NUP62, SLU7]
GO:0016236;macroautophagy;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;39.83166466328102;5.244474134527214;0.0013331299701091492;0.5584436629936305;[BECN1, GABARAPL1, CALCOCO2, UBQLN1, C6orf106, DYNLL2]
GO:2000772;regulation of cellular senescence;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;54.37826267282118;6.250713103064308;0.0018199915144001952;0.6427820713687392;[MAP3K3, NUAK1, ARNTL]
GO:0016358;dendrite development;6.0;0.8259837884571596;0.7361122068187242;9.260799472366804;32.63417926892749;6.343086423195323;0.0010922366112764486;0.647506047256038;[LST1]
GO:2000773;negative regulation of cellular senescence;7.0;1.0;0.8509193652572005;9.628524252492122;164.4250159730019;7.004484905440688;0.005503157311709213;0.7091290490632969;[MAP3K3]
GO:0008298;intracellular mRNA localization;4.0;0.7508913569872202;0.6254456784936101;8.781226392104918;25.834908722458497;7.379178354882098;8.646711450323476E-4;0.6273715242355574;[CASC3]
GO:0043536;positive regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;355.43002650478036;5.8067817141283475;0.011895923120858621;0.7122000987644093;[MAP3K3, SP1, CIB1]
GO:0080009;mRNA methylation;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;441.6717237220076;7.379178354882098;0.014782355114230749;0.7736121494158466;[WTAP]
GO:0097352;autophagosome maturation;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.599019797332524;0.0012734203321220245;0.6277151911823093;[GABARAPL1, UBQLN1, SNAP29]
GO:1903828;negative regulation of cellular protein localization;6.0;0.6023560406934092;0.6242983329368491;7.901303304401638;40.94940422013033;5.085725745451326;0.0013705397071766031;0.5832045637229588;[NSFL1C, TP53INP2, PPFIA1, OTUD7B]
GO:0010923;negative regulation of phosphatase activity;9.0;0.7866048967936545;0.7895430735771163;9.362821086759116;265.75489588375854;5.142344639450834;0.008894577201350937;0.659220369185286;[ELL]
GO:0035360;positive regulation of peroxisome proliferator activated receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;186.95064880168647;7.697632086000634;0.006257069970731893;0.7445766281117727;[STARD10]
GO:0055012;ventricular cardiac muscle cell differentiation;7.0;1.0;0.8509193652572005;9.628524252492122;47.302935560632505;8.16763571524637;0.001583186683336236;0.7686126355688037;[RXRA]
GO:0042176;regulation of protein catabolic process;6.0;0.5945822691631375;0.6204114471717133;8.214830917184116;56.791667214012804;3.8826707934156186;0.001900765992470805;0.5216802775280761;[DDB1, ITCH, CSNK2A1, ZFAND2A, ATPIF1, CLEC16A, VPS11, UBQLN1, PSME2, NUDT15, ARNTL]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[ONECUT2, ELL, WBP2, INTS10, ARID4A, HOXC13, ARNTL, POLR2B, TRIM24, ZNF768, EP300, POLR2G, IER2, GTF2I, TBP, NFYC, INTS3, PBX3, ARNT, GRHL1, USF2, FLI1, CDK9, TFCP2, COPS5, SP1, NFIC, TFEC, INTS4, LCOR, TAF7]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[CLK1, ERN1, BCR, MAP3K3, MKNK2, TRIM24, CLK4]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CDK9, CREBBP, TBP, RXRA, POLR2B, NPPA, TAF7, POLR2G, RORA, MED6, GTF2I]
GO:0006368;transcription elongation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;5.459585514144159;0.015969835568764485;0.675444082270312;[CDK9, ELL, POLR2B, POLR2G]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[SETX, TBX1, RXRA, SYNJ1]
GO:0000381;regulation of alternative mRNA splicing, via spliceosome;10.0;1.0;0.9152410118609203;9.628524252492122;185.80693659341267;5.649939242635378;0.00621879095239513;0.704179167478338;[WTAP, RBM5]
GO:0035357;peroxisome proliferator activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;25.568165535828406;7.697632086000634;8.557434906291208E-4;0.7167775754447168;[RXRA]
GO:0072703;cellular response to methyl methanesulfonate;5.0;1.0;0.7902410118609202;9.628524252492122;119.1082179217261;9.777073627680469;0.003986444863403435;0.7902410118609202;[TP53INP1]
GO:1904780;negative regulation of protein localization to centrosome;7.0;1.0;0.8509193652572005;9.628524252492122;73.78875676133134;9.083926447120524;0.0024696432832320894;0.8154717862087246;[NSFL1C]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[ARNTL]
GO:0007221;positive regulation of transcription of Notch receptor target;12.0;1.0;0.9481203125901445;9.628524252492122;1467.8987330058965;6.8867018697843045;0.04912924957061573;0.8003065664753022;[CREBBP, EP300]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[ANKRD17, CD4, DEFB1, RNASE3, LYST]
GO:0043951;negative regulation of cAMP-mediated signaling;8.0;0.7866048967936545;0.7683024483968273;9.417215158824915;239.89301649848343;6.8867018697843045;0.008029003372506139;0.7271862538851576;[UBE2B]
GO:1900745;positive regulation of p38MAPK cascade;12.0;1.0;0.9481203125901445;9.628524252492122;1761.632567075866;6.7325511899570465;0.05896025665364957;0.7924232935401965;[MAP3K3, KARS]
GO:0010508;positive regulation of autophagy;7.0;0.7192862368539868;0.710562483684194;9.040737587590003;216.89043707272492;5.132682728539097;0.007259127740103463;0.6134049986888465;[BECN1, CALCOCO2, TP53INP2, ATPIF1, TP53INP1, CLEC16A]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[CDKN1C, CIITA, NAB1, ARID4A, OTUD7B, CASC3, IKZF2, SMG5, YY1, EIF4ENIF1, NIPBL, SAP130, DPF2, TRIM24, WWC3, EP300, LRRFIP1, ZNF564, UPF2, TLE4, UPF1, SND1, ERN1, OLFM1, EID1, ILF3, PTRH2, MTF2, LCOR, EIF4E2, DCP2, HDAC3, ZNF350, HDAC1, FOXG1, GLG1, ARNTL, RXRA, U2AF2, TPR, TP53INP1, POLR2G, SUDS3, ZNF189, RPL19, IRX1, BBS2, DR1, CREBBP, UBE2I, NFYC, CNOT10, CDK9, CNOT6, PAN3, HIST3H2A, CNOT1, NFIC, SP3, ZNF658, TAF7, CNOT8]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[UBE2I, LRRC29, UBE2B, RNF38, SYVN1, FBXL15, ANAPC11, ARNTL, PSMD8, DDB1, KBTBD4, TRIM9, NSFL1C, ITCH, KCTD10, PSMB1, UBQLN1, FBXL3, ANAPC5, MAN1B1, RFFL, C18orf25]
GO:0070193;synaptonemal complex organization;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.24116723228514;6.641579411751319;7.10922751455178E-4;0.6298916918429109;[UBE2B]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[ITCH, CREBBP, EP300]
GO:0071044;histone mRNA catabolic process;10.0;0.9326813400603323;0.8815816818910864;9.60383163990175;834.8214523265239;7.292166977892469;0.027940722718839572;0.7881627702307852;[UPF1, DCP2]
GO:0070076;histone lysine demethylation;10.0;0.811012628672052;0.8207473261969463;9.439282252853593;347.1026298901722;6.444869117505266;0.011617212650338075;0.7448319182472036;[UBE2B]
GO:0032510;endosome to lysosome transport via multivesicular body sorting pathway;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;127.43112785876568;8.390779266560578;0.004265005168863507;0.7800242071602487;[LYST]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[CLK1, ERN1, MAST3, STK38, MKNK2, STK38L, CAMK1]
GO:0030213;hyaluronan biosynthetic process;8.0;1.0;0.875;9.628524252492122;506.6998597758615;7.8311634786251565;0.01695878830643033;0.7754860644832351;[ABCC5]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[BCR, ABR, ADORA3, TP53INP1, CLASP1]
GO:2000323;negative regulation of glucocorticoid receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;234.23542340630428;7.9853141584524145;0.007839648823214116;0.7833693374183408;[ARNTL]
GO:0061158;3'-UTR-mediated mRNA destabilization;11.0;1.0;0.9324289523296623;9.628524252492122;2713.9359790271515;7.138016298065211;0.09083299483423062;0.7974674377644215;[UPF1]
GO:0006344;maintenance of chromatin silencing;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.24116723228514;8.390779266560578;7.10922751455178E-4;0.7193458537639684;[UBE2B]
GO:0042753;positive regulation of circadian rhythm;4.0;0.8259837884571596;0.6629918942285797;9.040737587590003;21.56673843117642;6.8867018697843045;7.21819326487013E-4;0.6021862538851576;[RORA, ARNTL]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[CIITA, HDAC3, ZNF350, HDAC1, FOXG1, OTUD7B, IKZF2, YY1, NIPBL, RXRA, SAP130, TPR, WWC3, EP300, LRRFIP1, SUDS3, ZNF564, ZNF189, TLE4, IRX1, DR1, CREBBP, UBE2I, EID1, CNOT1, NFIC, SP3, MTF2, LCOR, TAF7]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[SP1, RAB8B]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[UBE2B, DVL3, SDC1]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTP4A1, DUSP23, PTPRA, DUSP28, SSH3]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[MKLN1, PARVG]
GO:0015721;bile acid and bile salt transport;9.0;0.9326813400603323;0.8625812952104552;9.5544162803384;89.96332036720499;6.375876246018314;0.003010991370958501;0.722303232910233;[RXRA]
GO:0035331;negative regulation of hippo signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;7.697632086000634;0.00799223380789131;0.7686572628545723;[WWC3]
GO:0042769;DNA damage response, detection of DNA damage;5.0;0.7866048967936545;0.6835434602577475;9.143016436710422;39.83823472227698;6.139487467954083;0.0013333498640710748;0.6042146864874571;[DDB1, WDR48, UBE2B]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[PHF3, SETD5, CIITA, ONECUT2, ELL, NAB1, INTS10, ARID4A, HOXC13, IKZF2, CHD1, YY1, NIPBL, ZMYM2, SAP130, NUP62, ZXDC, DPF2, TRIM24, ZNF768, EP300, ZNF326, LRRFIP1, ZNF688, ZNF564, IER2, GTF2I, TLE4, TBP, CSNK2A1, BUD31, COMMD3, ARNT, ZFX, SND1, MED29, ERN1, EID1, ILF3, ZNF519, TFEC, LCOR, VGLL4, ZNF394, HDAC3, ZNF350, HDAC1, WBP2, FOXG1, ZNF20, RLF, ARNTL, POLR2B, TP53INP2, TP53INP1, POLR2G, SUDS3, ASCC3, ZNF189, TRAPPC2, TBX1, ZNF462, DR1, NFYC, INTS3, PBX3, CNOT10, GRHL1, USF2, FLI1, SOX30, CDK9, CNOT6, IRAK1BP1, TFCP2, COPS5, CNOT1, POLR3C, SP1, NFIC, SP3, ZNF658, INTS4, TAF7, CNOT8, ZNF532, ZNF410]
GO:0031098;stress-activated protein kinase signaling cascade;6.0;0.7980440201809971;0.722142322680643;9.193206181234276;55.4262366053078;5.142344639450834;0.0018550662588052154;0.5861000565951415;[MAP3K3, CCM2]
GO:1904685;positive regulation of metalloendopeptidase activity;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;1125.0280967694966;9.083926447120524;0.0376536779393224;0.8969813732811862;[MBP]
GO:0006470;protein dephosphorylation;7.0;0.7586651285174919;0.7302519295159464;9.223059144383958;177.1697810635027;4.458953633836253;0.005929713129744359;0.5789504614541361;[PPP1CB, PTP4A1, PPP1CC, DUSP23, PTPRA, CTDSP2, SSU72, DUSP28, SSH3, PPM1G]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[RORA, ARNTL]
GO:0000245;spliceosomal complex assembly;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;66.59596265062147;6.444869117505266;0.002228906937441061;0.6805102716434839;[SNRPG, USP39, RBM5]
GO:1904209;positive regulation of chemokine (C-C motif) ligand 2 secretion;11.0;1.0;0.9324289523296623;9.628524252492122;1006.4404243716295;9.083926447120524;0.03368465526614197;0.8969813732811862;[MBP]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[CIITA, AHCTF1, ONECUT2, ELL, ARID4A, OTUD7B, RORA, DDX41, HOXC13, AATF, IKZF2, CHD1, YY1, NIPBL, ZMYM2, SAP130, GATAD1, ZXDC, DPF2, ZNF768, WWC3, EP300, LRRFIP1, ZNF564, IER2, GTF2I, TLE4, TBP, NCOA6, BUD31, SSU72, ZFP91, ARNT, SENP2, ZFX, MED6, TOX4, EID1, THAP6, GAL, ZNF519, MTF2, TFEC, LCOR, ZNF394, HDAC3, ZNF350, HDAC1, WBP2, FOXG1, ZNF20, TRAK1, RLF, ARNTL, RXRA, TPR, SCAP, SUDS3, ZNF189, IRX1, TBX1, ZNF462, DR1, CREBBP, UBE2I, NFYC, PBX3, FBXL15, GRHL1, USF2, FLI1, SOX30, SETX, CDK9, TFCP2, COPS5, CNOT1, SP1, NFIC, SP3, ZNF658, TAF7, CAMK1, ZNF532, ZNF410]
GO:0000132;establishment of mitotic spindle orientation;8.0;0.9326813400603323;0.8413406700301662;9.582004236857228;227.84740072539455;6.641579411751319;0.007625847452931234;0.7146506799819907;[NSFL1C, PAFAH1B1]
GO:0010845;positive regulation of reciprocal meiotic recombination;10.0;0.8933024483968273;0.861892236059334;9.57973408832269;926.7265706833982;8.67846133901236;0.031016704321007574;0.8590579283277371;[UBE2B]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[TBX1, BECN1, HDAC3, CSNK2A1, UBE2B, SPHK2, HDAC1, DOCK8, SYVN1, CIB1, AATF, SETX, DDB1, ITCH, CFDP1, SON, COPS5, PTRH2, NUP62, CASP2, VDAC2, RFFL, SNCB]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[HRK, ATPIF1, G0S2, BBC3, ABR, GAL, PTRH2, RPS6KA2, TP53INP1, CASP2, SUDS3, SERINC3, ECT2, RBM5]
GO:0071864;positive regulation of cell proliferation in bone marrow;6.0;1.0;0.8231203125901445;9.628524252492122;63.05258358394898;7.9853141584524145;0.0021103132289136558;0.7314896500084853;[MAP3K3]
GO:0034115;negative regulation of heterotypic cell-cell adhesion;8.0;1.0;0.875;9.628524252492122;130.132988179366;7.57984905034425;0.004355434002277579;0.7626338329336335;[MBP]
GO:0070534;protein K63-linked ubiquitination;11.0;0.9326813400603323;0.8987696223598284;9.577230958104572;157.60047254366168;6.166155715036245;0.00527474598481953;0.747766442352181;[ITCH, UBE2B, ZFP91]
